Adherence to national guidelines for initiation of antiretroviral regimens in HIV patients: A Danish nationwide study

British Journal of Clinical Pharmacology

Volumn 72, Issue 1, 2011, Pages 116-124

  Petersen, Tonny S ^a   Andersen, Stig E ^a   Gerstoft, January ^b   Thorsteinsson, Kristina ^c   Larsen, Carsten S ^d   Pedersen, Gitte ^e   Pedersen, Court ^f   Obel, Niels ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antiretroviral therapy; Guideline adherence; HIV

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; ARTICLE; DENMARK; FEMALE; HEALTH CARE PLANNING; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DENMARK; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUIDELINE ADHERENCE; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; REGRESSION ANALYSIS; STATE MEDICINE; TREATMENT OUTCOME;

EID: 79958755052     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03935.x     Document Type: Article

References (24)

1. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, Vaeth M, Obel N. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146: 87-95.
2. Grol R, Dalhuijsen J, Thomas S, Veld C, Rutten G, Mokkink H. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ 1998; 317: 858-61.
3. Lugtenberg M, Zegers-van Schaick JM, Westert GP, Burgers JS. Why don't physicians adhere to guideline recommendations in practice? An analysis of barriers among Dutch general practitioners. Implement Sci 2009; 4: 54.
4. Okechukwu I, Mahmud A, Bennett K, Feely J. Choice of first antihypertensive - are existing guidelines ignored? Br J Clin Pharmacol 2007; 64: 722-5.
5. Cocohoba J, Wang QJ, Cox C, Gange SJ, Cohen M, Glesby M, DeHovitz JA, Greenblatt RM. Consistency of initial antiretroviral therapy with HIV treatment guidelines in a US cohort of HIV-infected women. J Acquir Immune Defic Syndr 2008; 47: 377-83.
6. Brook MG, Curtis H, Johnson MA. Findings from the British HIV Association's national clinical audit of first-line antiretroviral therapy and survey of treatment practice and maternity care, 2002. HIV Med 2004; 5: 415-20.
7. Holodniy M, Hornberger J, Rapoport D, Robertus K, MaCurdy TE, Lopez J, Volberding P, Deyton L. Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004). J Acquir Immune Defic Syndr 2007; 44: 20-9.
8. Lohse N, Hansen AB, Jensen-Fangel S, Kronborg G, Kvinesdal B, Pedersen C, Larsen CS, Moller A, Willumsen L, Obel N. Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study. Scand J Infect Dis 2005; 37: 338-43.
9. Cressey D. Health economics: life in the balance. Nature 2009; 461: 336-9.
10. Toussi M, Ebrahiminia V, Le TP, Cohen R, Venot A. An automated method for analyzing adherence to therapeutic guidelines: application in diabetes. Stud Health Technol Inform 2008; 136: 339-44.
11. Jamtvedt G, Young JM, Kristoffersen DT, O'Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2006; 2: CD000259.
12. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-70.
13. Shekelle PG, Kravitz RL, Beart J, Marger M, Wang M, Lee M. Are nonspecific practice guidelines potentially harmful? A randomized comparison of the effect of nonspecific versus specific guidelines on physician decision making. Health Serv Res 2000; 34: 1429-48.
14. Grilli R, Lomas J. Evaluating the message: the relationship between compliance rate and the subject of a practice guideline. Med Care 1994; 32: 202-13.
15. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP. Therapeutic-class wars - drug promotion in a competitive marketplace. N Engl J Med 1994; 331: 1350-3.
16. Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G, Johnson M, Dunn DT, Orkin C, Anderson J, Schwenk A, Leen C, Sabin CA. Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med 2008; 9: 47-56.
17. Hoegh S, Lohse N, Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Laursen AL, Kvinesdal B, Moller A, Obel N. [Changes in immunological status among newly-diagnosed HIV-infected patients in Denmark 1995-2005]. Ugeskr Laeger 2008; 170: 740-4.
18. Kitahata MM, Dillingham PW, Chaiyakunapruk N, Buskin SE, Jones JL, Harrington RD, Hooton TM, Holmes KK. Electronic human immunodeficiency virus (HIV) clinical reminder system improves adherence to practice guidelines among the University of Washington HIV Study Cohort. Clin Infect Dis 2003; 36: 803-11.
19. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, Athey LA, Keesey JW, Goldman DP, Berry SH, Bozzette SA. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 1999; 281: 2305-15.
20. Larsen MV, Omland LH, Gerstoft J, Røge BT, Larsen CS, Pedersen G, Obel N, Kronborg G. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1 infected patients: a nationwide population-based cohort-study. Addiction 2010; 105: 529-35.
21. Turner BJ, Fleishman JA, Wenger N, London AS, Burnam MA, Shapiro MF, Bing EG, Stein MD, Longshore D, Bozzette SA. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med 2001; 16: 625-33.
22. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, Back DJ. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001; 51: 213-7.
23. Lohse N, Obel N, Kronborg G, Laursen A, Pedersen C, Larsen CS, Kvinesdal B, Sorensen HT, Gerstoft J. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. AIDS 2005; 19: 815-22.
24. Audelin AM, Lohse N, Obel N, Gerstoft J, Jorgensen LB. The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther 2009; 14: 995-1000.